Related Experiment Videos
Amphotericin B intralipid formulation: stability and particle size
J Y Ranchère1, J F Latour, C Fuhrmann
1Department of Anesthesiology, Cancer Center Léon Bérard, Lyon, France.
The Journal of Antimicrobial Chemotherapy
|June 1, 1996
Summary
Intralipid deoxycholate amphotericin B is not a stable formulation for treating fungal infections. This in-vitro study found precipitate and particle size increases, indicating potential risks with this amphotericin B delivery system.
Area of Science:
- Mycology
- Pharmacology
- Pharmaceutical Technology
Background:
- Amphotericin B is a critical antifungal agent for systemic infections.
- Its clinical utility is often limited by significant toxicity.
- Intralipid formulations are explored to improve drug delivery and reduce toxicity.
Purpose of the Study:
- To evaluate the in-vitro compatibility and stability of deoxycholate amphotericin B when formulated with Intralipid.
- To assess the physical characteristics of Intralipid deoxycholate amphotericin B solutions.
Main Methods:
- In-vitro assessment of deoxycholate amphotericin B solutions.
- Two dilution methods were used: deoxycholate amphotericin B in 5% dextrose and Intralipid, or deoxycholate amphotericin B in Intralipid alone.
- Solution stability and particle size were analyzed.
Main Results:
- Deoxycholate amphotericin B solutions in Intralipid exhibited instability.
- A clear yellow precipitate formed in the tested formulations.
- Significant increases in particle size (1.5-4-fold) were observed.
Conclusions:
- Intralipid deoxycholate amphotericin B is not a stable or recommended formulation.
- The observed instability and particle aggregation suggest potential risks for routine administration.
- Further research into safer amphotericin B delivery systems is warranted.